got a research services agreement with
involving protein and molecular targets associated with circulating tumor cells
Terms weren't disclosed.
"The list of pharmaceutical partners and biomarkers continues to expand," Immunicon said. "Our collaborations span across protein biomarkers, phosphoproteins and a variety of FISH assays to study gene amplification in a number of different carcinomas. We believe that our development work will advance the understanding of cancer biology as well as accelerate the time to market for promising new drugs."